Antibiotic resistance genes identified
By analysing large volumes of DNA data, researchers have identified 76 new types of antibiotic-resistant genes...
List view / Grid view
By analysing large volumes of DNA data, researchers have identified 76 new types of antibiotic-resistant genes...
Researchers have identified tools that may allow for the manipulation of genes that influence bacteria’s predatory behaviour...
Researchers have identified four pathogens that are responsible for the vast majority of diarrheal illnesses - leading the way for potential new treatments...
Polyphor achieves first milestone from Wellcome Trust for the development of antibiotics against Gram-negative multi drug - resistant pathogens...
Scientists have discovered a link between a major mechanism of antibiotic resistance and resistance to the common disinfectant triclosan...
LifeArc, the UK medical research charity previously known as MRC Technology; The Centre for Drug Research and Development (CDRD); and the Defence Science and Technology Laboratory (Dstl), have announced a collaboration to identify antibacterial drug targets.
Scientists have given new superpowers to an antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections.
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating foetal malformations can develop when infection occurs during pregnancy.
Researchers develop bacteria-fighting wound dressing made with the help of crustaceans…
Pfizer has launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
24 January 2017 | By
Author and Scientific Director Jean de Gunzburg, from Da Volterra, will present keynote speech at 19th annual Superbugs summit...
Experts at EUCAST have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at the University of Oxford have been working with two major EU-funded projects to deliver a novel antibiotic programme for clinical development...